ArticleDrug and alcohol dependence reports2026
Characterizing patterns of opioid and stimulant use by route and associations with non-fatal overdose and xylazine use in people who have injected drugs from Baltimore, MD, 2023-2024.
Article in Drug and alcohol dependence reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Daily patterns of opioid and stimulant use and associated risk-behavior outcomes: A cohort study.Addictive behaviors · 2026Article
- Higher prevalence of non-fatal overdose with opioid and stimulant use compared to use of opioids alone.Drug and alcohol dependence · 2026Article
- Crack/cocaine use to manage xylazine exposure in fentanyl in Connecticut: findings from a convergent mixed methods study.Harm reduction journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: The fourth wave of the overdose epidemic in the United States (US) is characterized by deaths involving fentanyl with stimulants. Understanding patterns of substance use as novel drugs continue to emerge is critical to inform overdose prevention. Among people with a history of injection drug use in Baltimore, MD, we examined opioid-stimulant use by route and the association of injection with non-fatal overdose and xylazine use. Methods: We included 1132 participants in the AIDS Linked to the IntraVenous Experience cohort with a study visit in 2023-2024. We characterized participants by self-reported past-six-month use of any opioid and any stimulant by route using descriptive statistics. Adjusted associations were estimated using targeted minimum loss-based estimation. Results: Most participants were Black (68 %), male (67 %), and older (median: 56 years). 53 % reported using both opioids and stimulants; these participants were more likely to report using other substances, non-fatal overdose, depressive symptoms, and homelessness. Among participants using both, those injecting both were more likely to report non-fatal overdose and xylazine use than those using by non-injection (overdose: PD = 22.3 %, 95 % CI= 17.2 %-27.5 %; xylazine: PD = 13.3 %, 95 % CI = 4.7 %-21.9 %). Conclusions: We provide one of the most comprehensive summaries of substance use during the fourth wave in Baltimore, a city with the highest rate of fatal overdose in the US during the study period. Use of multiple substances was common, and many participants reported injection. Overdose prevention should be targeted to those injecting both drugs as this pattern had heightened overdose risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.